Type II Diabetes - Houston TX (Clinical Trial # 14026)

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.
Browse Studies

City: Houston
State: TX
Zip Code: 77074
Study summary: In this randomized, double-blind, double dummy parallel group trial, the efficacy and safety of once daily oral administration of the fixed dose combination (FDC) of linagliptin/pioglitazone will be investigated in type 2 diabetic patients with insufficient glycaemic control.
Qualified participants must: • Have a diagnosis of type 2 diabetes mellitus prior to informed consent
• Have insufficient glycaemic control (HbA1c ≥ 7.0 to≤ 10.5% at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy within 10 weeks prior to start of the run-in period (date of Visit 2)
• Be 18-80 years of age at start date of Visit 1 (Screening)
• Have BMI ≤ 45 kg/m2 (Body Mass Index) at start date of Visit 1 (Screening)
Participants may receive: Stipend for participation and time.
Clinic Profile: View Clinic Profile

Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials or take the Participation Quiz to find out if you are a good candidate for clinical trial participation.